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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder that is typically fatal
within 3–5 years of diagnosis. While motoneuron death is the defining characteristic of ALS, the events that
underlie its pathology are not restricted to the nervous system. In this regard, ALS muscle atrophies and weakens
significantly before presentation of neurological symptoms. Since the skeletal muscle L-type Ca2+ channel (CaV1.1) is
a key regulator of both mass and force, we investigated whether CaV1.1 function is impaired in the muscle of two
distinct mouse models carrying an ALS-linked mutation.
Methods: We recorded L-type currents, charge movements, and myoplasmic Ca2+ transients from dissociated flexor
digitorum brevis (FDB) fibers to assess CaV1.1 function in two mouse models expressing a type 1 Cu/Zn superoxide
dismutase mutant (SOD1G93A).
Results: In FDB fibers obtained from “symptomatic” global SOD1G93A mice, we observed a substantial reduction of
SR Ca2+ release in response to depolarization relative to fibers harvested from age-matched control mice. L-type
current and charge movement were both reduced by ~40 % in symptomatic SOD1G93A fibers when compared to
control fibers. Ca2+ transients were not significantly reduced in similar experiments performed with FDB fibers obtained
from “early-symptomatic” SOD1G93A mice, but L-type current and charge movement were decreased (~30 and ~20 %,
respectively). Reductions in SR Ca2+ release (~35 %), L-type current (~20 %), and charge movement (~15 %) were also
observed in fibers obtained from another model where SOD1G93A expression was restricted to skeletal muscle.
Conclusions: We report reductions in EC coupling, L-type current density, and charge movement in FDB fibers
obtained from symptomatic global SOD1G93A mice. Experiments performed with FDB fibers obtained from
early-symptomatic SOD1G93A and skeletal muscle autonomous MLC/SOD1G93A mice support the idea that events
occurring locally in the skeletal muscle contribute to the impairment of CaV1.1 function in ALS muscle independently
of innervation status.
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Background
Amyotrophic lateral sclerosis (ALS), known commonly
as Lou Gehrig’s disease in the USA or motoneurone dis-
ease in the UK, is an adult-onset neurodegenerative
disorder that is usually lethal within 3 to 5 years of initial
diagnosis [1, 2]. As a consequence of disrupted nerve-
muscle communication, afflicted individuals progres-
sively lose control of voluntary muscle function and die
most frequently from respiratory failure. Nearly a quarter
of familial ALS cases have been linked to point mutations
in the type 1 Cu/Zn superoxide dismutase (SOD1) en-
zyme, which functions to mitigate cellular oxidative stress
[3]. Since these mutations are autosomal dominant, trans-
genic mice overexpressing ALS-linked SOD1 mutations
have proven to be useful models for investigation of ALS
pathogenesis [4, 5].
Two independent groups have found that skeletal
muscle-targeted, transgenic overexpression of SOD1G93A
causes profound muscle atrophy [6, 7] and initiates
motoneuron death [7]. These congruent reports reinforce
earlier challenges to the dogma that ALS is solely a neuro-
logical disorder and support the “dying-back” phenomenon
by which motor unit loss and associated muscle function
precede the death of motor neurons (reviewed in refs.
[8–11]). Additional support for this view is provided
by the observations that destruction of neuromuscular
junctions has been linked to oxidative stress induced
by tissue-specific breakdown of muscle mitochondria
[12] and trophic factors secreted from the skeletal
muscle promote motoneuron survival in an ALS
model by stabilizing neuromuscular junctions (e.g.,
IGF-1, GDNF) [13–15].
In the skeletal muscle, CaV1.1 functions both as the
voltage-sensor for excitation-contraction (EC) coupling
and as an L-type Ca2+ channel [16–18]. CaV1.1’s role as
voltage-sensor is firmly established [19], but recent work
has also revealed that L-type Ca2+ entry maintains myo-
plasmic Ca2+ levels during repetitive activity [20, 21]
augments muscle contraction [22], engages excitation-
transcription coupling [23], regulates energy expenditure
[24], and promotes development of neuromuscular
junctions [25]. Thus, aberrant CaV1.1 activity may pro-
foundly affect skeletal muscle biology.
The question of whether CaV1.1 function is disrupted
during the progression of ALS was originally posed over
20 years ago [26–28], but the experimental approach
used to investigate this premise left much ambiguity. In
these earlier studies, serum of ALS patients was acutely
applied to normal cut wild-type rat extensor digitorum
longus (EDL) fibers and the Vaseline-gap voltage-clamp
technique was used to record L-type currents and gating
charge movements [26, 27]; L-type currents and intra-
membrane gating charge movements were both found
to be reduced. Similarly, acute IgG application also
produced inhibitory effects on single CaV1.1 channels
in planar lipid bilayers [28]. In the time that has
passed since the experiments that employed acute ap-
plication of ALS IgG were performed, it has become
evident that that muscle dysfunction in ALS manifests
early and slowly over time. Fortunately, a number of
ALS mouse models have been developed since then,
including SOD1G93A transgenic lines [4, 29–31].
Here, we provide the first comprehensive voltage-clamp
assessment of CaV1.1 function in the muscle of an engi-
neered mammalian model of ALS. Specifically, we utilized
both global SOD1G93A mice and mice expressing
SOD1G93A only in skeletal muscle to systematically inves-
tigate whether CaV1.1 function is compromised during the
progression of the disease. We found substantial
reductions in myoplasmic Ca2+ transient amplitude, peak
L-type current density, and maximal intramembrane
charge movement in flexor digitorum brevis (FDB) fibers
obtained from “symptomatic” congenic SOD1G93A mice.
Consistent with a progressive muscle defect, we observed
lesser reductions in L-type current amplitude and charge
movement in FDB fibers obtained from “early-symptom-
atic” SOD1G93A mice in which widespread denervation
had yet to occur. To investigate the possibility that events
occurring in muscle contribute, at least in part, to the im-
pairment of CaV1.1 function, we performed voltage-clamp
experiments with FDB fibers of mice expressing
SOD1G93A autonomously in skeletal muscle. In these ex-
periments, we observed significant reductions in EC coup-
ling, charge movement, and peak L-type current
amplitude.
Methods
Ethical information/animals
All procedures involving mice were approved by the
University of Colorado-Anschutz Medical Campus
Institutional Animal Care and Use Committee
(91813(05)1D). Male congenic SOD1G93A mice
(B6.Cg-Tg(SOD1*G93A)1Gur/J; 32 transgene copies)
and age-matched male C57BL/6J mice (both Jackson
Laboratories, Bar Harbor, ME) were used at two time
points based on the criteria for disease progression de-
scribed by Hatzipetros et al. [31]: (1) “symptomatic” and
(2) “early-symptomatic.” Nine symptomatic mice pre-
sented classical ALS symptoms (i.e., tremor, abnormal
gait, comprised ability to stand on hindquarters, etc.)
when they were sacrificed at 149 ± 1 days. Six mice from
the early-symptomatic cohort were largely devoid of overt
symptoms when they were sacrificed at 105 ± 1 days.
Age-matched C57BL/6J mice were used as back-
ground wild-type controls for both symptomatic and
early-symptomatic global SOD1G93A mice (eight and
seven mice, respectively). Seven MLC/SOD1G93A mice
were sacrificed at (111 ± 1 days) [6]. In this case, six
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age-matched FVB/NJ mice were used as the background
wild-type control strain. The dissimilar backgrounds
precluded direct comparisons between global SOD1G93A
and MLC/SOD1G93A strains.
Dissociation of FDB fibers
The FDB muscles were dissected in cold (~4 °C) Rodent
Ringer’s solution (in mM: 146 NaCl, 5 KCl, 2 CaCl2, 1
MgCl2, 10 HEPES, pH 7.4 with NaOH). Muscles were
then digested in a mild collagenase solution (155 Cs-
aspartate, 10 HEPES, 5 MgCl2, pH 7.4 with CsOH, sup-
plemented with 1 mg/ml BSA, and 1 mg/ml collagenase
type IA (Sigma-Aldrich, Saint Louis, MO) with agitation
at 37 °C for ~1 h. Following digestion, the collagenase
solution was replaced with dissociation solution (140
Cs-aspartate, 10 Cs2EGTA, 10 HEPES, 5 MgCl2, pH 7.4
with CsOH, supplemented with 1 mg/ml BSA) and mus-
cles were triturated gently with a series of fire-polished
glass Pasteur pipettes of descending bore. Dissociated FDB
fibers destined for electrophysiological experiments were
then plated onto ECL (Millipore, Billerica, MA)-coated
35-mm plastic culture dishes (Falcon, Tewksbury, MA).
For Ca2+ imaging experiments, FDB fibers were plated
onto laminin (Invitrogen, Eugene, OR)-coated 35-mm
culture dishes with glass coverslip bottoms (MatTek,
Ashland, MA). Experiments were performed with FDB
fibers 1–6 h following dissociation.
Assessment of SR Ca2+ store content
Freshly dissociated FDB fibers were washed with Ca2
+/Mg2+-free Ringer’s solution (in mM: 146 NaCl, 5 KCl,
10 HEPES, and 11 glucose, pH 7.4, with NaOH) twice
and loaded with 5 μM Fluo 3-AM (Invitrogen) dissolved
in Rodent Ringer’s solution for 20–30 min. Fibers were
then washed three times in Rodent Ringer’s solution
with gentle agitation. Fluo 3-AM-loaded fibers bathed in
Rodent Ringer’s solution were then placed on the stage
of an LSM META scanning laser confocal microscope
(Carl Zeiss, Inc., Jena, Germany) and viewed under
×10 magnification. N-benzyl-p-toluenesulfonamide
(BTS; 100 μM; Sigma-Aldrich) was always present in
the bath solution (∼25 °C) to prevent contractions.
The Fluo-3 dye was excited with the 488 nm line of
an argon laser (30 mW maximum output, operated at
50 % or 6.3 A, attenuated to 1–2 %). The emitted
fluorescence was directed to a photomultiplier
equipped with a 505-nm long-pass filter. Confocal
fluorescence intensity data were digitized at 8 bits,
with the photomultiplier gain and offset adjusted such
that maximum pixel intensities were no more than
∼70 % saturated and cell-free areas had close to zero
intensity. Application of 4-chloro-m-cresol (4-CmC; Pfaltz
and Bauer, Waterbury, CT) via a manually operated,
gravity-driven global perfusion system was used to deplete
the SR of Ca2+. Fluorescence amplitude data are expressed
as ΔF/F, where F represents the baseline fluorescence be-
fore the application of 4-CmC, and ΔF represents the
change in fluorescence during the application of 4-CmC.
Electrophysiology and whole-cell recordings of
myoplasmic Ca2+ transients
Borosilicate patch pipettes had resistances of ≤1.0 MΩ
when filled with internal solution, which consisted of
(mM): 140 Cs-aspartate, 10 Cs2-EGTA, 5 MgCl2, and 10
HEPES, pH 7.4 with CsOH. FDB fibers that were se-
lected for voltage-clamp experiments were glossy, had
rounded ends, and cross-striations. Fibers meeting our
visual criteria were dialyzed in the whole-cell configur-
ation for >20 min prior to recording. To record changes
in intracellular Ca2+ from FDB fibers, the pentapotas-
sium salt form of Fluo 3 single wavelength Ca2+ indica-
tor dye (Invitrogen) was added to the standard internal
solution (see above) for a final concentration of 200 μM.
The external solution contained (mM): 145 TEA-
methanesulfonic acid, 10 CaCl2, 10 HEPES, 2 MgCl2, 1
4-aminopyridine, 0.1 anthracene-9-carboxylic acid, 0.002
tetrodotoxin, pH 7.4 with TEA-OH. Ten micromolar
BTS was added to the standard external solution for all
whole-cell experiments. Following the establishment of
the whole-cell configuration, the dye was allowed to dif-
fuse into the cell interior for no less than 20 min. A
100 W mercury illuminator and a set of fluorescein fil-
ters were used to excite the dye present in the voltage-
clamped fiber. A computer-controlled shutter was used
to block illumination in the intervals between test
potentials. Fluorescence emission was measured by
means of a fluorometer apparatus (Biomedical Instru-
mentation Group, University of Pennsylvania). Fluores-
cence data are expressed as ΔF/F, where ΔF represents
the change in peak fluorescence from baseline during
the test pulse and F is the fluorescence immediately
prior to the test pulse minus the average background
fluorescence. The peak value of the fluorescence change
(ΔF/F) for each test potential (V) was fitted according
to:
ΔF=Fð Þ ¼ ΔF=Fð Þmax= 1þ exp VF−Vð Þ=kF½ f g; ð1Þ
where (ΔF/F)max is the maximal fluorescence change, VF
is the potential causing half the maximal change in
fluorescence, and kF is a slope parameter.
All electrophysiological data were acquired with an
Axon 200B patch-clamp amplifier and a CV 203BU
headstage (both Molecular Devices, Sunnyvale, CA).
L-type Ca2+ currents were recorded with the same exter-
nal solution used to record myoplasmic Ca2+ transients
described above. A solution containing (in mM): 145
TEA-methanesulfonic acid, 10 CaCl2, 10 HEPES, 2
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MgSO4, 1 4-aminopyridine, 0.1 anthracene-9-carboxylic
acid, 0.002 tetrodotoxin, 1 LaCl3, 0.5 CdCl2, pH 7.4 with
TEA-OH were used to record intramembrane gating
charge movements. Linear components of leak and
capacitive current were corrected with −P/4 online sub-
traction protocols. Output filtering was at 2–5 kHz and
digitization was either at 5 kHz (currents) or 10 kHz
(charge movements). Cell capacitance (Cm) was deter-
mined by integration of a transient from −80 to −70 mV
using Clampex 10.3 (Molecular Devices) and was used to
normalize charge movement (nC/μF) and current ampli-
tude (pA/pF). The average value of Cm for all fibers used
in the study was 2.4 ± 0.1 nF (n = 160 fibers; please see
Additional file 1: Figure S1 for Cm data for each experi-
mental group). To minimize voltage error, the time con-
stant for the decay of the whole-cell capacity transient was
reduced as much as possible using the analog compensa-
tion circuit of the amplifier; the average values of τm and
Ra were 1.0 ± 0.0 ms and 456 ± 21 kΩ, respectively.
Current-voltage (I-V) curves were fitted according to:
I ¼ Gmax  V − V revð Þ = 1 þ exp − V − V 1=2
 
= kG
  
;
ð2Þ
where I is the normalized current for the test potential
V, Vrev is the reversal potential, Gmax is the maximum
channel conductance, V1/2 is the half-maximal activation
potential and kG is the slope factor. For charge move-
ments, the initial non-linear outward transient “QON”
was normalized to Cm and plotted as a function of test
potential (V) and the resultant QON −V relationships
were fitted according to:
QON ¼ Qmax= 1þ exp VQ−V
 
=kQ
  
; ð3Þ
where Qmax is the maximal QON, VQ is the potential
causing movement of half the maximal charge, and kQ is
a slope parameter. All electrophysiological and Ca2+ im-
aging experiments were performed at room temperature
(~25 °C).
Immunoblotting
The hindlimb muscles from wild-type and SOD1G93A
mice (tibialis anterior, gastrocnemius, and FDB) were
promptly removed following sacrifice, flash-frozen in
liquid nitrogen, and stored at −80 °C for later use. At a
later time, muscle tissue was homogenized by centrifu-
gation with aluminum beads (NextAdvance, Averill Park,
NY) in lysis buffer (50 mM Tris, 1 % SDS, Bio-Rad,
Hercules, CA). Sample protein concentration was deter-
mined using the Bradley method (BCA assay kit,
ThermoFisher, Pittsburgh, PA); lysates were divided
into 30–50 μg aliquots. After addition of Laemmli
buffer (Bio-Rad), proteins were separated by standard
SDS-PAGE (10 % gels; Bio-Rad), transferred to
nitrocellulose and non-specific immunoreactivity was
blocked with 5 % non-fat dry milk (Kroger, Cincinnati,
OH). Primary antibodies used for immunoblotting were
mouse anti-CaV1.1 (also referred to as mAB 1A; 1:1000;
ThermoScientific, Rockford, IL), mouse α-actin (1:1000;
Sigma-Aldrich), and rabbit histone H3 (1:1000; Cell Sig-
naling, Danvers, MA). Goat anti-mouse and anti-rabbit
HRP-conjugated secondary antibodies were obtained from
Southern Biotech (1:10000; Birmingham, AL). Blots were
visualized with SuperSignal West Pico kit (ThermoFisher)
viewed on a FluorChem HD2 scanner (Alpha Innotech,
San Leandro, CA). Blots were stripped using Restore
Western Blot Stripping Buffer (ThermoScientific). Cellular
CaV1.1 protein levels measured using ImageJ densitometry
(National Institutes of Health, Bethesda, MD) and were
normalized to α-actin expression in the same sample (i.e.,
lane).
Analysis
All data are presented as mean ± SEM. Statistical
comparisons were made by two-tailed, unpaired t test
with P < 0.05 considered significant. Figures were
made using the software program SigmaPlot (version
11.0, SSPS Inc., San Jose, CA).
Results and discussion
EC coupling is impaired in symptomatic SOD1G93A FDB
fibers
Like humans afflicted with ALS, mice engineered to
carry ALS-linked mutations in SOD1 display substantial
muscle atrophy and decreased specific force [30, 32].
Declines in specific force that resemble that occurring in
ALS [30] have previously been attributed to reduced
membrane expression of CaV1.1 [33–35] and experimental
knockdown of CaV1.1 expression causes marked atrophy
[36]. Taken together, these observations raise the question
of whether the primary function of CaV1.1—voltage-sensor
for EC coupling—is impaired in skeletal muscle of a mutant
SOD1 ALS model. To address this question, we dialyzed
flexor digitorum brevis (FDB) fibers isolated from congenic
SOD1G93A mice and age-matched C57BL/6J wild-type con-
trol mice with cell-impermeant Fluo 3 Ca2+ indicator dye
and recorded depolarization-induced myoplasmic Ca2+
transients in the whole-cell configuration (cf. ref. [37]). As
shown in Fig. 1a, we observed robust SR Ca2+ release in
response to step depolarizations in Fluo 3-loaded wild-
type control fibers (ΔF/F = 2.3 ± 0.4, n = 6). By contrast,
depolarization-induced SR Ca2+ release was substan-
tially decreased in symptomatic SOD1G93A fibers (ΔF/F
= 1.0 ± 0.1, n = 9; P < 0.01; Fig. 1b, c; Table 1); no change
in the voltage-dependence of transient activation was
apparent (Table 1).
To determine whether the ~55 % reduction in
Ca2+ transient amplitude in SOD1G93A fibers was a
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consequence of a depleted SR Ca2+ store, we measured
changes in myoplasmic Ca2+ levels in response to applica-
tion of the RyR agonist 4-chloro-m-cresol (4-CmC;
1 mM). In these experiments (Fig. 2a–c), we observed no
apparent differences in the response to 4-CmC between
symptomatic SOD1G93A and age-matched wild-type fibers
(ΔF/F = 3.5 ± 0.3, n = 35, and 3.0 ± 0.2, n = 33, respectively;
P > 0.05).
L-type currents and intramembrane charge movement
are reduced in symptomatic SOD1G93A FDB fibers
The impairment of EC coupling (Fig. 1) without appre-
ciable SR Ca2+ store depletion (Fig. 2) suggests an alter-
ation in CaV1.1 expression and/or function. To
investigate this possibility, we recorded L-type Ca2+
currents and intramembrane charge movements from
SOD1G93A fibers and wild-type fibers. Representative
L-type current families from wild-type and symptomatic
SOD1G93A fibers are shown in Fig. 3a, b, respectively. We
observed a ~40 % reduction in the peak current density in
symptomatic SOD1G93A fibers relative to that observed in
age-matched wild-type fibers (Idens = −5.4 ± 0.5 pA/pF,
n = 12 vs. −8.7 ± 0.8 pA/pF, n = 10, respectively, at +20 mV;
P < 0.001; Fig. 3c). In addition, we observed a similar
(~40 %) reduction in maximal charge movement for
SOD1G93A fibers compared to wild-type fibers
(Qmax = 14.1 ± 1.4 nC/μF, n = 10 vs. 23.4 ± 0.8 C/μF,
n = 9, respectively; P < 0.005; Fig. 3d–f ).
We also measured protein levels of CaV1.1 in the tibi-
alis anterior, gastrocnemius, and FDB muscles via west-
ern blot. As shown in Fig. 4a—top, we observed a clear
reduction in CaV1.1 levels in tibialis anterior prepara-
tions (band intensity relative to α-actin = 0.40 ± 0.03 for
wild-type and 0.16 ± 0.02 for symptomatic; P < 0.001;
both N = 4; Fig. 4a—top panel) that reflected our electro-
physiological measurements (Fig. 3). For gastrocnemius,
total CaV1.1 expression was only marginally insignificant
(relative band intensity = 0.32 ± 0.04 and 0.20 ± 0.04 for
wild-type and symptomatic, respectively; P = 0.074; N = 4:
Fig. 1 EC coupling is impaired in symptomatic global SOD1G93A FDB fibers. Representative voltage-induced myoplasmic Ca2+ transients
elicited by 25 ms depolarizations from −80 to −60, −40, −20, 0, and 20 mV from FDB fibers harvested from a wild-type C57BL/6J mouse
(a) and a symptomatic SOD1G93A mouse (b). The peak ΔF/F-V relationships for wild-type and symptomatic SOD G93A fibers are presented
in panel (c). Ca2+ transients were evoked at 0.1 Hz by test potentials ranging from −70 mV through +60 mV in 10 mV increments. The
smooth curves are plotted according to Eq. 1 with the respective fit parameters shown in Table 1. The numbers of analyzed fibers are
indicated in parentheses. Throughout, error bars represent ± SEM
Table 1 Ca2+ transient fit parameters
Data are given as mean ± SEM, with the numbers in parentheses indicating
the number of fibers tested. Data were fit by Eq. 1. The triple thin lines
separate three distinct experimental groups: (1) symptomatic, (2) early-
symptomatic, and (3) MLC/SOD1G93A. Significant differences within each group
(i.e., between a group of SOD1G93A -expressing fibers and the corresponding
age-matched background control fibers) are indicated (* denotes P < 0.05;
unpaired t test
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Fig. 4b—top panel). A reduction in CaV1.1 plasma mem-
brane expression in FDB fibers was not detectable by
western blot (relative band intensity = 0.54 ± 0.09 and 0.62
± 0.12 for wild-type and symptomatic, respectively;
Fig. 4c—top panel). It is important to note here that quan-
tification of these biochemical data was extremely difficult
because the expression level of all reference gene products
used in our experiments also changed. α-actin was found
to be the most stable marker, and we used it to calculate
changes in CaV1.1 band intensity (Fig. 4a–c—middle
panels). Still, α-actin is not an ideal reference as it does
fluctuate somewhat between wild-type and symptomatic
SOD1G93A muscle. The levels of histone 3 were greatly
and evenly increased in the symptomatic SOD1G93A
tibilias anterior and gastrocnemius muscles (Fig. 4a,
b—bottom panels) and unchanged in FDB (Fig. 4c—bot-
tom panel) preparations. These experiments further
supported the idea that any observed downregulation of
CaV1.1 was not a consequence of uneven gel loading.
Likewise, Coomassie staining of the same samples used
in western blots was similar between wild-type and
SOD1G93A muscle (Additional file 2: Figure S2A–C).
Impaired CaV1.1 function in early-symptomatic SOD1
G93A
FDB fibers
Since muscle weakness and atrophy are known to pre-
cede overt locomotor effects of SOD1G93A expression
(e.g., abnormal gait, tremor, etc.) [38, 39], we sought to
determine whether the observed impairment of CaV1.1
activity in SOD1G93A mouse muscle began in the early
stages of presentation. We first examined EC coupling in
FDB fibers of early-symptomatic SOD1G93A mice and
age-matched wild-type mice. In this case, we observed
no significant change in Ca2+ transient amplitude for
early-symptomatic SOD1G93A fibers relative to wild-type
fibers (2.0 ± 0.3 ΔF/F, n = 8 vs. 1.7 ± 0.3 ΔF/F, n = 9,
respectively; P > 0.05 Fig. 5a–c). Despite the lack of sig-
nificant effect on Ca2+ transient amplitude, we observed
a ~30 % decrease in peak L-type current amplitude be-
tween early-symptomatic SOD1G93A fibers and wild-type
control fibers (Idens = −6.9 ± 0.9 pA/pF, n = 7 vs. 10.0 ± 0.9
pA/pF, n = 6, respectively; P < 0.05; Fig. 6a–c). Charge
movements were also reduced (~20 %) in early-
symptomatic SOD1G93A fibers relative to wild-type fibers
(Qmax = 18.8 ± 1.1 nC/μF, n = 8 vs. 23.9 ± 1.7 nC/μF, n = 8,
respectively; P < 0.05; Fig. 6d–f; Table 2).
In Fig. 7, we summarize our results with symptomatic
and early-symptomatic SOD1G93A FDB fibers. There, EC
coupling (ΔF/F), L-type channel current amplitude (peak
IL) and intramembrane charge movement (Qmax) are
normalized by the corresponding age-matched wild-type
control value for each parameter. For symptomatic
SOD1G93A fibers, the reductions in EC coupling, channel
function, and charge movement are quite evident
(Fig. 7—black bars). Moreover, these impairments of CaV1.1
function were already developing in early-symptomatic
Fig. 2 SR Ca2+ store content is similar in wild-type and symptomatic SOD1G93A FDB fibers. Representative records of 4-CmC (1 mM)-induced SR
Ca2+ release in dissociated FDB fibers harvested from a wild-type mouse (a) and from a symptomatic SOD1G93A mouse (b). Insets show images of
Fluo 3-loaded fibers before 4-CmC application (left) and at the peak of fluorescence (right). c Data summary
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SOD1G93A mice before substantial denervation had oc-
curred (Fig. 7—white bars), suggesting that muscle-specific
events are contributing to SOD1G93A-dependent alterations
in CaV1.1 function.
EC coupling, L-type currents, and charge movement are
reduced in FDB fibers expressing SOD1G93A autonomously
in the skeletal muscle
Our experiments with early-symptomatic SOD1G93A
mice raise the possibility that the reduction of CaV1.1
expression precedes overt neurological symptoms of
ALS. Nonetheless, a degree of uncertainty exists con-
cerning the contribution of denervation. On a more
stringent level, the innervation profiles of the individual
fibers used in our patch-clamp experiments were
virtually impossible to assess accurately. To determine
nerve-independent effects, we utilized a mouse model
where transgenic expression of SOD1G93A is limited to
skeletal muscle (MLC/SOD1G93A) [6]. This mouse line
enabled us to examine whether events occurring locally
in skeletal muscle can cause impaired CaV1.1 function
because substantial neuromuscular junction defects in
such models do not develop until at least 8 months of
age ([6, 7]; A.M., unpublished results).
We recorded from fibers obtained from 4-month-old
MLC/SOD1G93A mice. In these experiments, myoplasmic
Ca2+ transients recorded from MLC/SOD1G93A fibers
were significantly reduced compared to their aged-
matched wild-type FVB/NJ counterparts (ΔF/F = 1.3 ± 0.2,
n = 9 vs. 2.1 ± 0.3, n = 6, respectively; P < 0.05; Fig. 8a–c).
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Fig. 3 L-type currents and charge movements are reduced in symptomatic SOD1G93A FDB fibers. Representative whole-cell recordings of L-type
currents elicited by 500 ms step depolarizations from −80 to −20, 0, 20, and 40 mV are shown for a wild-type FDB fiber (a) and a symptomatic
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test potentials ranging from −40 mV through +80 mV in 10 mV increments. Representative recordings of intramembrane charge movements
elicited by 25 ms depolarizations from −80 to −40, −20, 0, and 20 mV are shown for a wild-type (d) and a symptomatic SOD1G93A fiber (e). f Q-V
relationships corresponding to the charge movements shown in panels (d) and (e). Charge movements were evoked at 0.1 Hz by test potentials
ranging from −70 mV through +50 mV in 10 mV increments. The smooth curves in panels (c) and (f) are plotted according to Eqs. 2 and 3,
respectively, with fit parameters displayed in Table 2
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As with global SOD1G93A fibers (Fig. 1), the changes in
Ca2+ transient amplitude were not attributable to compro-
mised SR Ca2+ stores as no significant difference in the
response to 4-CmC between MLC/SOD1G93A and age-
matched wild-type fibers was evident (ΔF/F = 5.0 ± 0.6,
n = 27, and 4.4 ± 0.3, n = 17, respectively; P > 0.05). We
also observed smaller (~20 %) L-type current ampli-
tudes in MLC/SOD1G93A fibers relative to wild-type
fibers (Idens = −14.5 ± 1.5 pA/pF, n = 9 vs. −18.4 ± 0.6
pA/pF, n = 12, respectively; P < 0.05; Fig. 9a–c). Charge
movements were reduced by similar degree (~15 %) in
MLC/SOD1G93A fibers (Qmax = 34.1 ± 1.7 nC/μF, n = 10
vs. 39.6 ± 1.1 nC/μF for wild-type, n = 10, respectively;
P < 0.05; Fig. 9d–f; Table 2). Taken together, our results
with MLC/SOD1G93A fibers indicate that muscle-specific
expression of SOD1G93A ultimately causes a reduction in
the total number of functional CaV1.1 channels present in
the transverse tubules.
Discussion
In this study, we found that FDB fibers harvested from
symptomatic global SOD1G93A mice had substantially re-
duced EC coupling relative to fibers of age-matched
wild-type mice (Fig. 1). The impairment of EC coupling
was not a consequence of a depleted SR Ca2+ store
(Fig. 2), but appeared to be the result of reduced L-type
Ca2+ channel membrane expression (though we cannot
discount the presence of electrically silent channels). In
particular, L-type Ca2+ current (Fig. 3a–c) and intramem-
brane charge movement (Fig. 3d–f ) were both decreased
Fig. 4 Western blot analysis of CaV1.1 protein levels in symptomatic SOD1
G93A skeletal muscle. a western blots of lysates obtained from four
different tibialis anterior (b) gastrocnemius muscles of age-matched wild-type and symptomatic SOD1G93A mice are shown (N = 4 for both
groups). In each case, the blots were probed with a monoclonal antibody directed to CaV1.1 (top panels), then stripped and reprobed sequentially
for α-actin (middle panels) and then histone H3 (bottom panels). A protein ladder standard resides in lane 1 of each blot; molecular weights are
indicated in kDa. c A western blot of lysates obtained from FDB muscles of age-matched wild-type and symptomatic SOD1G93A mice are shown
(N = 2 for both groups). The blot was first probed with a monoclonal antibody directed to CaV1.1 (top panel) and then stripped and reprobed
sequentially with antibodies directed to α-actin (middle panel) and then histone H3 (bottom panel). For each blot, changes in expression were
determined by comparing the intensity of each CaV1.1 band in the top panel to the corresponding actin band the middle panel. For each panel,
similar results were observed in at least three experiments
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Fig. 5 EC coupling is not significantly impaired in early-symptomatic SOD1G93A FDB fibers. Representative Ca2+ transients elicited by
25 ms depolarizations from −80 to −60, −40, −20, 0, and 20 mV from fibers harvested from a wild-type mouse (a) and from an
early-symptomatic SOD1G93A mouse (b). ΔF/F-V relationships are shown in (c)
Fig. 6 L-type currents and charge movements are reduced in early-symptomatic SOD1G93A FDB fibers. Representative L-type currents elicited by
500 ms depolarizations from −80 to −20, 0, 20, and 40 mV are shown for a wild-type FDB fiber (a) and an early-symptomatic SOD1G93A fiber (b). c
Peak I-V relationships corresponding to the current families are shown in panels (a) and (b). Representative charge movement recordings elicited
by 25 ms depolarizations from −80 to −40, −20, 0, 20 mV are shown for a wild-type (d) and a pre-symptomatic SOD1G93A fiber (e). f Q-V relationships.
The smooth curves in panels (c) and (f) are plotted according to Eq. 2 and Eq. 3, respectively, with fit parameters displayed in Table 2
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by ~40 % in symptomatic SOD1G93A FDB fibers. The ob-
served reductions in CaV1.1 function in symptomatic
SOD1G93A fibers resembled the effect of application of
ALS patient serum to normal rat extensor digitorum
longus muscle [26, 27], but our results imply that these
impairments develop more slowly over time.
Our data indicating that EC coupling and L-type
current were compromised in symptomatic SOD1G93A
muscle fibers contrast with those of another group who
found that depolarization-dependent Ca2+ transients
were slightly augmented in SOD1G93A mice (B6SJL-
Tg(SOD1*G93A)1Gur/J) as a consequence of insufficient
local mitochondrial Ca2+ buffering near the neuromus-
cular junction [40, 41]. Our findings also differ with
those of another study which also examined Ca2+ hand-
ling in FDB fibers obtained from symptomatic SOD1G93A
mice (B6.Cg-Tg(SOD1*G93A)1Gur/J). In this latter study
[42], the authors observed virtually no difference in the
amplitude of Ca2+ transients evoked by maximal field
stimulation frequencies (100 Hz) using ratiometric
Ca2+-sensitive dyes. It was concluded that the ability
of CaV1.1 to engage EC coupling was normal in symptom-
atic SOD1G93A superficial gastrocnemius muscle because
western blots showed no change in CaV1.1 expression
[42]. By contrast, our western blot analysis of whole-cell
lysates obtained from symptomatic SOD1G93A tibialis an-
terior muscles indicated a clear reduction in total CaV1.1
expression (Fig. 4a). We did not observe significant differ-
ences for either gastrocnemius or FDB (Fig. 4b, c), though
the band intensity difference in gastrocnemius was mar-
ginal (P = 0.074). The ambiguous nature of our biochem-
ical results underscores the critical importance of our
voltage-clamp approach to determine the relative number
of functional CaV1.1 channels in the plasma membrane.
One reasonable explanation for the observed decreases
in Ca2+ transient amplitude, peak L-type current density,
and maximal charge movement is that SOD1G93A-ex-
pressing muscle undergoes fast-twitch (type IIb or IIx)
to slow or intermediate (type I or type Ia, respectively)
fiber-type switching [6, 30]. In an earlier study, slow-twitch
rat soleus fibers were found to support voltage-dependent
SR Ca2+ release only about half as well as fast-twitch fibers
dissected from EDL of the same animals [43, 44]. Likewise,
radioactive 1,4-dihydropyridine binding of the soleus was
reduced ~50 % compared to that of EDL in the same study.
In view of this difference in CaV1.1 expression between
general fiber types, it is possible that we recorded from a
population more heavily weighted in type I or type IIa fi-
bers and that our data reflect fiber-type switching. Never-
theless, the dramatic alteration in the expression profile of
Table 2 Conductance and charge movement fit parameters
Data are given as mean ± SEM, with the numbers in parentheses indicating the number of FDB fibers tested. Conductance and charge movement data were fit by
Eqs. 2 and 3, respectively. As in Table 1, the triple thin lines separate three distinct experimental groups: (1) symptomatic, (2) early-symptomatic, and (3) MLC/
SOD1G93A. Again, significant differences within each group are indicated (* denotes P < 0.05; *** denotes P < 0.001; unpaired t test)
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CaV1.1 that accompanies fiber-type switching appears to be
a downstream consequence of mutant SOD1 expression.
Future experiments with more complex models that enable
the distinction amongst fiber types in live cells are required
to investigate this idea further.
Importantly, we also found that the impairment of
CaV1.1 function in SOD1
G93A mice began to develop
prior the presentation of classical ALS symptoms.
Though the reduction in depolarization-induced Ca2+
transients were not significantly reduced in early-
symptomatic SOD1G93A muscle fibers (Fig. 5), decreased
L-type current amplitude and intramembrane charge
movement were clearly evident (Fig. 6). A number of ex-
planations could account for this apparently discordant
result. For example, the early-symptomatic SOD1G93A
mice may have had a dissimilar RyR (type 1 or type 3)
complement than the symptomatic mice or there have
been a compensatory reversion to a juvenile RyR1 splice
variant (ASI+) that supports greater SR Ca2+ release in
response to depolarization [45, 46]. In any event, the re-
sults of our experiments with early-symptomatic
SOD1G93A fibers suggested that the impairment of
CaV1.1 function manifested in symptomatic SOD1
G93A
fibers arises, at least in part, from signals that originate in
muscle (Figs. 5, 6, and 7). To test this idea, we assessed
CaV1.1 function in fibers obtained from 4-month-old
MLC/SOD1G93A mice in which expression of the mutant
SOD1 protein is restricted to skeletal muscle. In these ex-
periments, we observed ~35, ~20, and ~15 % reductions in
Ca2+ transient amplitude, peak L-type current density, and
maximal charge movement, respectively (Figs. 8 and 9).
The reductions in L-type current amplitude and charge
movement resembled the reductions in the parameters ob-
served in early-symptomatic global SOD1G93A fibers. Inter-
estingly, the impact of muscle-specific expression of
SOD1G93A on EC coupling was greater than that observed
in early-symptomatic global fibers. Previous ultrastructural
analysis of the MLC/SOD1G93A strain suggests that con-
current uncoupling of triad junctions with transverse tu-
bules may amplify the EC coupling impairment [6].
Together, the ultrastructural and electrophysiological
changes induced by muscle-specific expression of
SOD1G93A can reasonably account for marked reductions
in specific force observed in both fast- and slow-twitch
hindlimb muscles of MLC/SOD1G93A mice [6]. Thus, the
Fig. 8 EC coupling is impaired in MLC/SOD1G93A FDB fibers. Representative Ca2+ transients elicited by 25 ms depolarizations from −80 to −60, −40,
−20, 0, and 20 mV in fibers obtained from a wild-type FVB/NJ mouse (a) and a MLC/SOD1G93A mouse (b). ΔF/F-V relationships are shown in (c)
Fig. 7 Summary of results obtained with global SOD1G93A fibers. EC
coupling (ΔF/F), L-type Ca2+ current (peak IL), and maximal charge
movement (Qmax) for early-symptomatic (105 ± 1 d; N = 6; white bars)
and symptomatic global SOD1G93A (149 ± 1 d; N = 9; black bars)
fibers are represented as a percentage of corresponding values for
the respective age-matched wild-type fiber groups
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results of our experiments with MLC/SOD1G93A fibers
support the idea that muscle-specific events also make a
significant contribution to ALS pathology, similar to what
has been observed previously with myotonic dystrophy
[47] and Huntington’s disease [48].
We did not observe a decrease in total membrane cap-
acitance in SOD1G93A-expressing fibers, indicating that
there was not substantial atrophy and/or loss of tubular
surface area in the fibers that we examined electrophysio-
logically (Additional file 1: Figure S1). Based on the
indisputable fact that atrophy is characteristic of both glo-
bal and muscle-targeted SOD1G93A muscles, we think that
our data are representative of a subpopulation of fibers
healthy enough to survive the dissociation process and to
meet the set visual criteria for voltage-clamp experiments
(see Methods). If this is indeed the case, the reductions in
voltage-dependent SR Ca2+ release, charge movement, and
L-type current in the entire population of SOD1G93A fibers
are likely more severe (and earlier onset) than we report.
Until recently, the involvement of CaV1.1 in the main-
tenance of muscle mass and composition was impossible
to investigate because mice null for CaV1.1 (dysgenic)
die immediately following parturition [49]. To circumvent
the perinatal lethality of CaV1.1 deletion, Piétri-Rouxel
and colleagues delivered anti-CaV1.1 siRNA to the mouse
hindlimb muscle with a serotype 1 Adeno-Associated
Virus (AAV1) vector [36]. Using this approach, they dem-
onstrated that targeted, long-term suppression of L-type
channel expression via induced exon-skipping produced
prominent atrophy and extensive fibrosis. This atrophic ef-
fect of experimental downregulation of CaV1.1 expression
suggested that pathological decreases in L-type channel ac-
tivity, such as those we have observed in the two
SOD1G93A models utilized in this study, may also lead to
muscle degeneration and, possibly, contribute to the
destabilization of neuromuscular junctions early in the pro-
gression of ALS. Our current work provides initial support
for this idea, but further work is needed to reveal the
Fig. 9 L-type currents and charge movements are reduced in MLC/SOD1G93A FDB fibers. Representative L-type currents elicited by 500 ms depolarizations
from −80 to −20, 0, 20, and 40 mV are shown for a wild-type FDB fiber (a) and an MLC/SOD1G93A fiber (b). c Peak I-V relationships corresponding to the
current families shown in panels (a) and (b). Representative charge movement recordings elicited by 25 ms depolarizations from −80 to −40, −20, 0, and
20 mV are shown for a wild-type (d) and an MLC/SOD1G93A fiber (e). f Q-V relationships corresponding to the charge movements shown in panels (d) and
(e). The smooth curves in panels (c) and (f) are plotted according to Eqs. 2 and 3, respectively, with fit parameters displayed in Table 2
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precise mechanism. The first step will be to determine
whether the downregulation of the channel and/or its auxil-
iary subunits occurs at the message level or post-
translationally. For the former, quantification of CaV1.1
subunit message levels by qRT-PCR should be revealing. In
regard to the latter, the chronic upregulation of expression
the RGK family small GTP binding protein Rad (Ras-like
Associated with Diabetes) — a potent constitutively active
inhibitor of CaV1.1 [50, 51]—has been demonstrated in
muscle of sporadic ALS patients of unknown aetiology and
two established familial ALS mouse models (SOD1G93A and
SOD1G86R) [52, 53]. The increases in muscle Rad expression
were attributed to elevated cellular oxidative stress levels
and coincided with the onset of spinal motoneuron death
[53]. Without being overspeculative, these observations raise
the possibility that such chronic enhancement of muscle
Rad expression may contribute to both atrophy and the
dissolution of neuromuscular junctions in human ALS [53].
Conclusions
We report that myoplasmic Ca2+ transient amplitude, L-
type current density, and intramembrane charge movement
are progressively downregulated in flexor digitorum brevis
(FDB) fibers obtained from SOD1G93A mice, the most
extensively utilized mouse model of familial ALS. We also
observed impairments of EC coupling, L-type current
density, and charge movement in fibers of mice expressing
SOD1G93A only in the skeletal muscle, signaling a muscle-
specific contribution to SOD1G93A-induced downregulation
of CaV1.1 expression and/or function. Since CaV1.1 is a
positive regulator of muscle mass, our results suggest that
altered CaV1.1 activity is a contributor to the muscle
remodeling that occurs in ALS patients prior to the presen-
tation of overt neurological symptoms.
Additional files
Additional file 1: Figure S1. Capacitance measurements. White bars
represent the average membrane capacitance (Cm) recorded from
symptomatic SOD1G93A, early-symptomatic SOD1G93A, and MLC/SOD1G93A
fibers. Black bars represent the average membrane capacitance recorded
from the appropriate wild-type control group (see “Methods” section). A
significant difference between wild-type FVB/NJ and MLC/SOD1G93A fibers
is indicated (*** denotes P < 0.001; unpaired t test). (PPTX 56.7 kb)
Additional file 2: Figure S2. >Coomassie staining. Coomassie staining
of gels containing the same samples used in the immunoblotting
experiments shown in Fig. 4: (A) tibialis anterior, (B) gastrocnemius,
and (C) FDB. (PPT 109 kb)
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